Compare Stitch Fix Inc (SFIX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Viatris Inc — how do they compare? Stitch Fix Inc trades at $3.94 (market cap $520.36M), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 38× Stitch Fix Inc's market cap, and Viatris Inc pays a 2.83% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.
| SFIX | VTRS | |
|---|---|---|
Market Cap | $520.36M | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $17.39 |
52-Week Low | $3.06 | $8.74 |
Enterprise Value | $408.08M | $32.00B |
Dividend Yield | — | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
